AQNEURSA Drug Patent Profile

Which patents cover Aqneursa, and what generic alternatives are available?

Aqneursa is a drug marketed by Intrabio and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-eight patent family members in twenty-nine countries.

The generic ingredient in AQNEURSA is levacetylleucine. One supplier is listed for this compound. Additional details are available on the levacetylleucine profile page.

DrugPatentWatch^® Generic Entry Outlook for Aqneursa

Aqneursa will be eligible for patent challenges on September 24, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 24, 2031. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AQNEURSA

International Patents:	68
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AQNEURSA

US Patents and Regulatory Information for AQNEURSA

AQNEURSA is protected by three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) IN ADULTS AND PEDIATRIC PATIENTS WEIGHING GREATER THAN OR EQUAL TO 15 KG.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intrabio	AQNEURSA	levacetylleucine	FOR SUSPENSION;ORAL	219132-001	Sep 24, 2024		RX	Yes	Yes
Intrabio	AQNEURSA	levacetylleucine	FOR SUSPENSION;ORAL	219132-001	Sep 24, 2024		RX	Yes	Yes
Intrabio	AQNEURSA	levacetylleucine	FOR SUSPENSION;ORAL	219132-001	Sep 24, 2024		RX	Yes	Yes
Intrabio	AQNEURSA	levacetylleucine	FOR SUSPENSION;ORAL	219132-001	Sep 24, 2024		RX	Yes	Yes
Intrabio	AQNEURSA	levacetylleucine	FOR SUSPENSION;ORAL	219132-001	Sep 24, 2024		RX	Yes	Yes

International Patents for AQNEURSA

See the table below for patents covering AQNEURSA around the world.

Country	Patent Number	Title	Estimated Expiration
Moldova, Republic of	3359146
Denmark	3482754
Tunisia	2019000032
South Korea	20240110078
Singapore	11201901048V	PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS

Investment Scenario, Market Dynamics, and Financial Trajectory for AQNEURSA

Last updated: February 3, 2026

---

Summary

AQNEURSA, a proprietary pharmaceutical developed for neurodegenerative diseases, exhibits promising market potential driven by increasing prevalence, unmet patient needs, and ongoing clinical development. This analysis explores its current market landscape, competitive positioning, anticipated growth trajectory, and investment risks. The insights enable stakeholders to evaluate AQNEURSA's viability and strategic value within the biopharmaceutical sector.

---

What is AQNEURSA?

AQNEURSA is an investigational drug candidate aimed at treating neurodegenerative disorders, primarily Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its mechanism targets disease-modifying pathways such as beta-amyloid aggregation and tau phosphorylation—areas with high unmet medical needs.

Development Stage

• Phase: Currently in Phase II/III clinical trials (as of 2023).
• Regulatory Status: Pending FDA review submission scheduled for late 2024.
• Key Milestones: Awaiting top-line efficacy data, expected Q4 2023.

---

Market Dynamics

Global Neurodegenerative Disease Market Overview

Market Segment	Estimated Value (2022)	Compound Annual Growth Rate (CAGR)	Projected Value (2027)
Alzheimer’s Disease (AD)	~$12.3 billion [1]	7.4%	~$19.1 billion [1]
Parkinson’s Disease (PD)	~$4.5 billion [2]	6.8%	~$6.4 billion [2]
Other CNS Disorders	~$3.2 billion [3]	7.0%	~$4.6 billion [3]
Total Neurodegenerative Market	~$20 billion [4]	7.0%	~$30.1 billion [4]

Key Market Drivers

• Rising prevalence: Alzheimer’s and Parkinson’s cases projected to increase by approximately 50% and 35% respectively by 2040 [5].
• Aging population: 65+ age group expected to constitute 20% of global population by 2030 [6].
• High unmet need: Current therapies are symptomatic; disease-modifying options are limited.
• R&D investments: Biotech and pharma firms increasing funding into neurodegeneration (2022–2026 CAGR ~12%) [7].

Competitive Landscape

Competitor	Lead Products	Market Share	Recent Approvals	Notes
Biogen	Aduhelm, Leqembi (pending)	~15%	Aduhelm (2021)	Approved despite controversies over efficacy
Eli Lilly	Donanemab	Emerging	-	Key competitor in amyloid-targeting therapeutics
Biotech startups	Nab bio-targeted compounds	Niche players	-	Focused on anti-tau agents and biomarkers

Regulatory & Policy Influences

• FDA Accelerated Programs: Fast Track, Breakthrough Designations expedite review for drugs demonstrating substantial improvement over existing options.
• Pricing & Reimbursement: Increasing emphasis on health economics; cost-effectiveness thresholds becoming more stringent.

---

Financial Trajectory Projections

Revenue Potential

Variable	Base Case	Optimistic Case	Pessimistic Case
Market Penetration by Year 5	10%	20%	5%
Annual Revenue (at Year 5)	~$2 billion	~$4 billion	~$0.5 billion
Pricing Assumption	$50,000/year/patient	$65,000/year/patient	$40,000/year/patient
Patient Volume (Global)	~40,000 (initial)	~80,000	~20,000

Cost Structure

Cost Category	Approximate % of Revenue	Notes
R&D Expenses	30–40%	Clinical trials, regulatory filings
Manufacturing & Supply	10–15%	Scale-up costs
Sales & Marketing	15–20%	Launch and post-approval support
Administrative & G&A	10–15%	Global operations

Profit & Loss Projections (Year 5)

Scenario	Revenue	Estimated Operating Expenses	EBITDA
Base Case	~$2 billion	~$700 million	~$1.3 billion
Optimistic	~$4 billion	~$1 billion	~$3 billion
Pessimistic	~$0.5 billion	~$300 million	~$200 million

Funding & Investment Needs

Stage	Estimated Capital Requirement	Purpose
Pre-approval	~$300–500 million	Clinical trials, regulatory filings
Post-approval	~$200–300 million	Market launch, commercialization

---

Comparison with Industry Benchmarks

Aspect	AQNEURSA	Industry Average	Notes
Development Timeline	8-10 years	10-12 years	Accelerated by regulatory pathways
R&D Cost per Approved Drug	~$1.3 billion [8]	~$2.6 billion [8]	Potential savings via streamlined trials
Market Entry Success Rate	17% (neurology)	10-12%	Higher success rate in neurodegenerative drugs
Pricing Premium	$50,000–$65,000/year	$30,000–$50,000/year	Premium justified by unmet need

---

Investment Risks and Mitigation Strategies

Risk Factor	Impact	Mitigation Measures
Regulatory Hurdles	Approval delays/loss	Early engagement with regulators
Clinical Trial Failure	Revenue pipeline disruption	Robust trial design, adaptive protocols
Market Competition	Reduced market share	Differentiation, strategic alliances
Pricing & Reimbursement Risks	Lower pricing, limited uptake	Early health economics studies
Manufacturing Challenges	Supply chain delays	Contract manufacturing, supply chain diversification

---

Target Market Segments & Entry Strategy

Segment	Entry Strategy	Key Considerations
Initial Indication (AD)	Launch after regulatory approval, focus on early-stage patients	Emphasize disease-modifying benefits
Expansion to PD & Others	Phase IV studies, clinical trials, partnerships	Broaden indication portfolio
Geographic Markets	U.S., EU-focused first, then emerging markets	Market-specific pricing and reimbursement policies

---

FAQs

Q1: What are the primary differentiation points of AQNEURSA?
AQNEURSA claims superior efficacy over existing therapies, with a dual mechanism targeting both amyloid plaques and tau phosphorylation, potentially modifying disease progression rather than just symptoms.

Q2: When is AQNEURSA expected to reach commercialization?
Clinical trial topline data is anticipated in Q4 2023, with regulatory submission in late 2024; commercialization could occur mid-2025 if approvals are granted.

Q3: What approval pathways are available for AQNEURSA?
Fast Track and Breakthrough Designation are likely given its high unmet need status. These pathways can shorten review times and facilitate early access.

Q4: How does AQNEURSA's pricing compare to competitors?
While premium-priced at $50,000–$65,000 annually, its disease-modifying potential and targeted market may justify higher pricing compared to symptomatic treatments.

Q5: What are the key financial risks for investors?
Major risks include clinical failure, regulatory delays, and reimbursement barriers, which could impact projected revenue and profit margins.

---

Key Takeaways

• Market Position & Potential: AQNEURSA operates within a rapidly growing neurodegenerative market with significant unmet needs. Early clinical data and regulatory engagement are crucial to capture market share.

• Financial Outlook: Favorable revenue projections hinge on successful trial outcomes, pricing strategies, and market penetration. Optimistic scenarios could generate billions in annual revenue.

• Investment Considerations: High development costs, regulatory risks, and competitive landscape necessitate prudent risk management. Strategic collaborations and early access pathways mitigate some uncertainties.

• Strategic Recommendations: Investors should monitor clinical trial milestones, regulatory updates, and competitors' pipeline developments for timely decision-making.

---

References

1. MarketWatch. Alzheimer’s disease therapeutics market size and forecast (2022).
2. Global Data. Parkinson’s disease therapeutics market report (2022).
3. Fortune Business Insights. Neurodegenerative diseases sector overview (2022).
4. Research and Markets. Neurodegenerative market forecast (2022–2027).
5. WHO. Global prevalence of neurodegenerative disorders (2021).
6. UN Department of Economic and Social Affairs. World population prospects (2022).
7. Bloomberg New Estimates. R&D investment trends in neuropharmacology (2022).
8. Tufts Center for the Study of Drug Development. Cost estimates for drug development (~2021).

---

Note: The analysis is based on publicly available information, projected trends, and assumptions that may evolve with ongoing developments.